Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck

BACKGROUND Previous Phase II trials evaluating paclitaxel as a single agent have produced objective response rates of 38–40%. However, in these studies patients had recurrent disease and had received previous treatment with chemotherapy, radiation, surgery, or some combination of the same. To the au...

Ausführliche Beschreibung